Arcturus Therapeutics
ARCT
120 hedge funds and large institutions have $146M invested in Arcturus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 36 increasing their positions, 37 reducing their positions, and 42 closing their positions.
71% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $1.14M
3% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 37
12% less funds holding
Funds holding: 136 → 120 (-16)
11.82% less ownership
Funds ownership: 95.22% → 83.4% (-12%)
33% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 42
69% less capital invested
Capital invested by funds: $477M → $146M (-$330M)
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.97M |
| 2 |
Two Sigma Advisers
New York
|
+$5.1M |
| 3 |
Two Sigma Investments
New York
|
+$4.94M |
| 4 |
Jane Street
New York
|
+$3.09M |
| 5 |
Millennium Management
New York
|
+$2.86M |
Top Sellers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$17.8M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$10.2M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.46M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.33M |
ARCT Hedge Fund Activity: Q4 2025 in Review
120 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2025, worth a combined $146M — down 69% from $477M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ARCT and 28 opened new positions — a net loss of 14 holders — while 37 trimmed existing stakes and 36 added.
The largest buyer was ARK Investment Management, adding an estimated $7.97M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $17.8M sold.
- 120 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2025, down from 136 in Q3 2025.
- Funds reported $146M of Arcturus Therapeutics stock for Q4 2025, down 69% quarter-over-quarter.
- 28 funds opened new Arcturus Therapeutics positions in Q4 2025 and 42 closed out, a net change of -14 holders.
- The largest Arcturus Therapeutics buyer in Q4 2025 was ARK Investment Management, an estimated $7.97M added.
- The largest Arcturus Therapeutics seller in Q4 2025 was Balyasny Asset Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2025.